Enveric Biosciences, Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. The company is an early-stage biosciences developer focused on psychedelic-derived drug candidates and, at the time, cannabinoid therapies for cancer care. It reported no revenue; margins are therefore not meaningful.
Key financial metrics
| Metric | Q2 2022 / June 30, 2022 | Comparable period / prior balance |
|---|---|---|
| Operating expenses | $4.71 million for Q2; $9.50 million for six months | $3.36 million for Q2 2021; $10.13 million for six months 2021 |
| Operating loss | $4.71 million for Q2; $9.50 million for six months | $3.36 million for Q2 2021; $10.13 million for six months 2021 |
| Net loss | $2.79 million for Q2; $7.31 million for six months | $0.91 million for Q2 2021; $4.16 million for six months 2021 |
| Net loss attributable to shareholders | $2.87 million for Q2; $7.40 million for six months | $0.91 million for Q2 2021; $4.16 million for six months 2021 |
| Net loss per share, basic and diluted | $2.73 for Q2; $7.78 for six months | $2.13 for Q2 2021; $10.62 for six months 2021 |
| Cash and cash equivalents | $18.01 million | $17.36 million at December 31, 2021 |
| Working capital | $17.04 million | Prior comparable working-capital figure not provided in the filing text |
| Total assets / liabilities | $28.57 million / $5.97 million | $26.72 million / $4.41 million at December 31, 2021 |
| Operating cash flow | $(9.13) million for six months | $(5.18) million for six months 2021 |
| Investing cash flow | $(0.56) million for six months | $(0.68) million for six months 2021 |
| Financing cash flow | $10.36 million for six months | $24.90 million for six months 2021 |
The balance sheet reports no conventional borrowing line; liabilities primarily comprise warrant and derivative liabilities, lease obligations, accounts payable and accruals, and deferred taxes. Q2 and six-month results include gains from revaluing warrant liabilities, which are non-cash and materially reduced reported net losses. The company recorded a $2.25 million six-month warrant fair-value gain, versus $6.27 million in the prior-year period.
Material changes versus prior periods
- Q2 operating expenses rose 40% year over year, mainly as research and development increased 141% to $2.12 million, driven by psychedelic research and development activity. General and administrative expenses rose 8% to $2.50 million.
- Q2 net loss increased to $2.79 million from $0.91 million, despite $1.97 million of warrant fair-value income; operating loss increased to $4.71 million.
- For the first six months, operating expenses decreased 6% as general and administrative costs fell 40%, principally from lower stock-based compensation. R&D rose 279% to $4.08 million. Net loss nevertheless widened to $7.31 million, reflecting substantially lower warrant fair-value gains than in 2021.
- Operating cash use increased by $3.95 million year over year. The company funded operations partly through a February 2022 stock-and-warrant offering that generated approximately $9.1 million net.
Outlook, risks and unusual items
- Management said cash resources, including approximately $7.2 million net proceeds from offerings completed July 26, 2022, were sufficient for expected funding requirements over the next year. It expects to need additional financing over the following years; no revenue or earnings guidance was provided.
- The planned spin-off of the cannabinoid clinical pipeline to majority-owned Akos was conditional on, among other things, Akos qualifying for Nasdaq listing. Enveric retained the psychedelic pipeline. If the spin-off does not occur or is abandoned under specified conditions, Enveric guarantees a put right on Akos preferred stock; the June 30 carrying amount was $637,840 and stated redemption value was approximately $1.008 million including accrued dividends.
- On July 14, 2022, the company effected a 1-for-50 reverse stock split. Share and per-share figures in the filing are retrospectively adjusted. On July 29, Nasdaq notified the company it had regained compliance with the minimum bid-price requirement.
- The company cited early-stage development and regulatory uncertainty, reliance on future financing, clinical and commercialization risks, foreign-currency exposure, and potential delays or failure of the spin-off. It had no material pending litigation reported.
- Disclosure controls were deemed ineffective as of June 30, 2022 because material weaknesses in internal control over financial reporting— including inadequate segregation of duties—continued. Management described remediation efforts but noted additional measures may be needed.
- The CFO notified the company on August 11 of his planned departure, effective September 9, 2022; the filing says it was not due to a disagreement with the company.
Important facts for investors to verify
- Whether the Akos spin-off proceeds, its listing conditions are met, and any resulting guarantee or put obligations become payable.
- Cash burn, remaining runway, and the company’s ability to raise capital on acceptable terms after the July 2022 financing.
- Progress, costs, and regulatory milestones for the psychedelic pipeline and the proposed separation of cannabinoid assets.
- Remediation and subsequent auditor or management assessments of the disclosed material weaknesses in internal controls.
- Potential dilution from outstanding warrants, preferred investment options, incentive-plan awards, and post-quarter financing.